ClinicalTrials.gg
CompletedNCT05338502Updated Oct 30, 2024Results posted

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

A Phase 1 interventional study of Selpercatinib and Ranitidine in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Jul 2019, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 9 weeks, inclusive of screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants of non- who are agreeable to take measures until study completion
  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study

Exclusion criteria

Exclusion Criteria:

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Have or used to have health problems or laboratory test results or readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Had blood loss of more than 500 milliliters (mL) within the previous 30 days of study screening
  • Require treatment with inducers or inhibitors of cytochrome P450 (CYP) within 14 days before the first dose of study drug through the end of Period 2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    160 milligram (mg) Selpercatinib

    Participants received a single oral dose of 160 mg Selpercatinib (Study Day 1).

    Drug: Selpercatinib

  • Experimental
    150 mg Ranitidine dosed with 160 mg Selpercatinib

    Participants received 150 mg ranitidine twice a day orally for 11 days (Study Days 8 to 18) with a single oral dose of 160 mg Selpercatinib (Study Day 12).

    Drug: Selpercatinib · Drug: Ranitidine

  • Experimental
    40 mg Omeprazole dosed with 160 mg Selpercatinib

    Participants received 40 mg omeprazole once daily for 11 days (Study Days 19 to 29) with a single oral dose of 160 mg Selpercatinib (Study Day 23).

    Drug: Selpercatinib · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

    PK: AUC0-t of Selpercatinib. The analysis of variance (ANOVA) model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric least squares (LS) means and the difference between treatment geometric LS means, as well as their corresponding 90% confidence intervals (CIs). The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  2. PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

    PK: AUC0-inf of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  3. PK: Percentage of Area Under the Plasma Concentration-Time Curve (AUC) That is Due to Extrapolation From Last Measurable Concentration to Infinity (%AUCextrap) of Selpercatinib

    PK: %AUCextrap of Selpercatinib

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  4. PK: Maximum Observed Plasma Concentration (Cmax) of Selpercatinib

    PK: Cmax of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  5. PK: Time of Maximum Observed Concentration (Tmax) of Selpercatinib

    PK: Tmax of Selpercatinib

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  6. PK: Apparent Volume of Distribution (Vz/F)

    PK: Vz/F of Selpercatinib

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  7. PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib

    PK: CL/F of Selpercatinib

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

  8. PK: Apparent Terminal Elimination Half-life (t½) of Selpercatinib

    PK: t½ of Selpercatinib

    Time frame: PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3

07

Results

Posted Oct 30, 2024

Participant flow

Period 1 - Day 1 to Day 8
Participant flow — Period 1 - Day 1 to Day 8
Milestone160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
Started2000
Received at least one dose of study drug2000
Completed2000
Not completed000
Period 2 - Day 8 to Day 19
Participant flow — Period 2 - Day 8 to Day 19
Milestone160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
Started0200
Completed0170
Not completed030
Withdrew: Withdrawal by subject020
Withdrew: Adverse event010
Period 3 - Day 19 to Day 29
Participant flow — Period 3 - Day 19 to Day 29
Milestone160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
Started0017
Completed0017
Not completed000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

PK: AUC0-t of Selpercatinib. The analysis of variance (ANOVA) model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric least squares (LS) means and the difference between treatment geometric LS means, as well as their corresponding 90% confidence intervals (CIs). The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Geometric mean · hour*nanograms per milliliter(h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
hour*nanograms per milliliter(h*ng/mL)160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib21600 ± 31.419100 ± 31.921000 ± 27.4
Statistical analysis
  • 160 mg Selpercatinib vs 150 mg Ranitidine Dosed With 160 mg Selpercatinib · ANOVA · Geometric least squares mean (lsm) ratio: 0.900 · 90% CI 0.797 to 1.02
  • 160 mg Selpercatinib vs 40 mg Omeprazole Dosed With 160 mg Selpercatinib · ANOVA · Geometric ls mean ratio: 0.990 · 90% CI 0.876 to 1.12
PrimaryPK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

PK: AUC0-inf of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Geometric mean · h*ng/mL
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
h*ng/mL160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib21800 ± 31.219900 ± 33.521100 ± 27.4
Statistical analysis
  • 160 mg Selpercatinib vs 150 mg Ranitidine Dosed With 160 mg Selpercatinib · ANOVA · Geometric ls mean ratio: 0.932 · 90% CI 0.829 to 1.05
  • 160 mg Selpercatinib vs 40 mg Omeprazole Dosed With 160 mg Selpercatinib · ANOVA · Geometric ls mean ratio: 1.00 · 90% CI 0.888 to 1.13
PrimaryPK: Percentage of Area Under the Plasma Concentration-Time Curve (AUC) That is Due to Extrapolation From Last Measurable Concentration to Infinity (%AUCextrap) of Selpercatinib

PK: %AUCextrap of Selpercatinib

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Median · percentage of (%) of AUCextrap
PK: Percentage of Area Under the Plasma Concentration-Time Curve (AUC) That is Due to Extrapolation From Last Measurable Concentration to Infinity (%AUCextrap) of Selpercatinib
percentage of (%) of AUCextrap160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160mg Selpercatinib
PK: Percentage of Area Under the Plasma Concentration-Time Curve (AUC) That is Due to Extrapolation From Last Measurable Concentration to Infinity (%AUCextrap) of Selpercatinib0.337 (0.136 to 3.00)0.818 (0.137 to 2.02)0.612 (0.103 to 1.59)
PrimaryPK: Maximum Observed Plasma Concentration (Cmax) of Selpercatinib

PK: Cmax of Selpercatinib. The ANOVA model was performed on the natural log (ln)-transformed PK parameters and included calculation of geometric LS means and the difference between treatment geometric LS means, as well as their corresponding 90% CIs. The ratios of geometric LS mean and 90% CI for the ratio of the PK parameter for each comparison was constructed using the exponentiation of the difference and the CIs from the ANOVA analyses.

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Geometric mean · ng/mL
PK: Maximum Observed Plasma Concentration (Cmax) of Selpercatinib
ng/mL160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
PK: Maximum Observed Plasma Concentration (Cmax) of Selpercatinib1650 ± 58.41330 ± 67.81220 ± 63.4
Statistical analysis
  • 160 mg Selpercatinib vs 150 mg Ranitidine Dosed With 160 mg Selpercatinib · ANOVA · Geometric ls mean ratio: 0.818 · 90% CI 0.680 to 0.985
  • 160 mg Selpercatinib vs 40 mg Omeprazole Dosed With 160 mg Selpercatinib · ANOVA · Geometric ls mean ratio: 0.782 · 90% CI 0.645 to 0.949
PrimaryPK: Time of Maximum Observed Concentration (Tmax) of Selpercatinib

PK: Tmax of Selpercatinib

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Median · hour
PK: Time of Maximum Observed Concentration (Tmax) of Selpercatinib
hour160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
PK: Time of Maximum Observed Concentration (Tmax) of Selpercatinib2.00 (1.00 to 3.00)1.83 (1.00 to 24.00)3.00 (1.50 to 6.00)
PrimaryPK: Apparent Volume of Distribution (Vz/F)

PK: Vz/F of Selpercatinib

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Geometric mean · liter
PK: Apparent Volume of Distribution (Vz/F)
liter160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
PK: Apparent Volume of Distribution (Vz/F)259 ± 44.2331 ± 59.1300 ± 48.6
PrimaryPK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib

PK: CL/F of Selpercatinib

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Geometric mean · liter per hour (L/h)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib
liter per hour (L/h)160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib7.35 ± 31.28.03 ± 33.57.58 ± 27.4
PrimaryPK: Apparent Terminal Elimination Half-life (t½) of Selpercatinib

PK: t½ of Selpercatinib

Time frame:
PK: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 post Selpercatinib dose on Day 1 - Period 1, Day 12 - Period 2, and Day 23 - Period 3
Reported as:
Geometric mean · hour
PK: Apparent Terminal Elimination Half-life (t½) of Selpercatinib
hour160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
PK: Apparent Terminal Elimination Half-life (t½) of Selpercatinib24.4 ± 35.429.3 ± 33.527.4 ± 30.1

Adverse events

Collected over Baseline through Day 37. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
160 mg Selpercatinib0/20 (0%)0/20 (0%)5/20 (25%)
150 mg Ranitidine Dosed With 160 mg Selpercatinib0/20 (0%)0/20 (0%)11/20 (55%)
40 mg Omeprazole Dosed With 160 mg Selpercatinib0/17 (0%)0/17 (0%)4/17 (23.5%)
Most frequent other events
Showing 10 of 15
Most frequent other events
Event160 mg Selpercatinib150 mg Ranitidine Dosed With 160 mg Selpercatinib40 mg Omeprazole Dosed With 160 mg Selpercatinib
DysmenorrhoeaReproductive system and breast disorders0/41/40/3
ConstipationGastrointestinal disorders3/202/202/17
Abdominal distensionGastrointestinal disorders0/200/202/17
DyspepsiaGastrointestinal disorders0/202/200/17
HeadacheNervous system disorders0/202/201/17
SomnolenceNervous system disorders0/202/200/17
InsomniaPsychiatric disorders0/202/201/17
Dry skinSkin and subcutaneous tissue disorders0/202/200/17
Erectile dysfunctionReproductive system and breast disorders1/160/160/14
DiarrhoeaGastrointestinal disorders0/200/201/17

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years0
Between 18 and 65 years20
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female4
Male16
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Study Participants
Hispanic or Latino5
Not Hispanic or Latino15
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American11
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Study Participants
United States20
08

Study locations

1 site
  • Covance Clinical Research Unit, Inc.
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Sep 2019, 1 month.

Results were first posted in Oct 2024, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
Apr 21, 2022
StartActual
Jul 8, 2019
Primary completionActual
Sep 3, 2019
CompletionActual
Sep 3, 2019
Results first posted
Oct 30, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05338502
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Jul 8, 2019
Primary completion
Sep 3, 2019
Completion
Sep 3, 2019
Results posted
Oct 30, 2024
Last update
Oct 30, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion